ClinicalTrials.gg
RecruitingNCT05281770Updated Oct 20, 2022

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

An observational study in Migraine, Migraine With Aura and Migraine Without Aura, sponsored by Austrian Migraine Registry Collaboration. Recruiting at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-20.

Sponsored by Austrian Migraine Registry Collaboration · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Migraine Disorders with a site in Austria — 4 open to participants now, 6 under way, 2 of them phase 3. Migraine Disorders · Austria.

Started
2022
with 3 others
Observational
3 of 20
3 open now
Registered
10th of 20
by date
Lead sponsor
1 of 20
Austrian Migraine Registry Collaboration

Among the 20 studies in Migraine Disorders with a site in Austria, this one is one of 4 that started in 2022, is one of 3 observational ones, and was the 10th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 20 studies in Migraine Disorders with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Migraine Disorders with a site in Austria, or all of them as a file.
02

Study summary

The present non-interventional study on migraine prevention with monoclonal CGRP antibodies adresses questions concering safety, swichting from one CGRP mab to another, efficacy on auras in the real world setting.

Read the detailed description

Introduction:

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CGRP-R) are an effective option for the preventative treatment in episodic and chronic migraine. All monoclonal antibodies against CGRP or CGRP-R have been proven efficacious in all various treatment endpoints (i.e. reduction of MMDs, improvement in Quality of Life etc.) in randomized phase 3 trials and were therefore approved by FDA and EMA. However, real world clinical experience/data in "non-study" patients is lacking as is data on long-term efficacy, elderly or data on switchers between antibodies that cannot be derived out of previous trials.

Phase 3 and 4 studies have addressed issues of efficacy and safety in highly selected clinical study populations and so far no safety concerns have emerged. However, long-term data are limited to a maximum period of 5 years and have been acquired in selected study cohorts probably not reflecting a "real world" patient population. It is a main goal of the study to acquire data on safety and efficacy in a real world setting where patients will be less selected than in clinical studies in terms of accompanying diseases or comorbidities. Another knowledge gap concerns the optimal procedure when switching the patient from one anti-CGRP therapy to another or being paused (and re-initiated) after a first successful treatment period. With specific evidence lacking, it is frequently recommended to wait several half-lives before initiating the next anti-CGRP therapy. Another unresolved question is whether non-responders to CGRP ligand blockers may respond to CGRP-receptor blockers and vice versa. While efficacy of anti-CGRP therapies has been demonstrated for migraine with and without aura, possible effects on the migraine auras per se have not been reported.

Phase 4 studies (non-interventional studies) on treatment with anti-CGRP therapies are being conducted in several countries in Europe. These are, however, limited to one specific substance. The proposed project will allow collecting data on the use of erenumab, fremanezumab, and galcanezumab on a nation- wide basis up to 36 months in a real-life setting.

The following knowledge should emerge from the registry:

Anti-CGRP therapies can be safely used in a wide spectrum of migraine patients with comorbidities and accompanying diseases over a long time period. There will be evidence how patients can be switched from one CGRP antibody to another. There will be an evidence base to switch anti-CGRP-therapies from ligand- to receptor- blockers or vice versa. Additionally the question whether a mAB even if effective should be paused or not after 1 year of treatment and what effect this pause might have will be addressed subsequently.

Methods Collected data will be entered in an electronic platform provided by Health Austria (https://goeg.at/) which has long-term experience in conducting and maintaining nation-wide registries, e.g. the Austrian Stroke Registry.

Non interventional study - The decision for therapy with an anti-CGRP monoclonal antibody/ CGRP antagonist is made by the treating physician and is NOT part of the Study. The study was approved by the relevant ethics committees and registered at a platform of the Austrian Agency for Health an Nutrition Safety at https://forms.ages.at/nis/. All patients treated in the headache centers are keeping headache diaries on paper or in electronic form as a standard of care procedure. Prospective and retrospective data collection from electronic charts is possible. Data are collected during routine visits which are scheduled in 3 months intervals. Collected data will be entered in an electronic platform provided by Health Austria (https://goeg.at/) in an anonymized form.

Study funding: Scientific reports concerning fremanezumab will be provideded to TEVA Austria, reports on erenumab to Novartis Austria and on galcanezumab to Eli Lilly Austria, based on financial compensation agreements.

03

Conditions studied

  • Migraine
  • Migraine With Aura
  • Migraine Without Aura
  • Chronic Migraine
  • Episodic Migraine

Keywords

  • Erenumab
  • Galcanezumab
  • Fremanezumab
  • CGRP-antibodies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Male or female adult patients of at least 18 years or older in whom CGRP mabs can be prescribed according to Austrian regulations. These include treatment failure or intolerability / contraindications of at least 3 prophylactic medications. Documentation of treatment in a headache diary on paper or in digital format.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • episodic or chronic migraine with or without aura
  • erenumab, fremanezumab or galcanezumab is prescribed as a standard of care treatment by treating physician Eptinezumab may be included as soon as available in Austria.

Exclusion criteria

Exclusion Criteria:

  • Off label use of erenumab, fremanezumab or galcanezumab
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Erenumab

    Patients will be treated with this drug within standard of care treatment

    Drug: Erenumab

  • Galcanezumab

    Patients will be treated with this drug within standard of care treatment

    Drug: Galcanezumab

  • Fremanezumab

    Patients will be treated with this drug within standard of care treatment

    Drug: Fremanezumab

Interventions

  • treatment with erenumab as chosen by treating physician

  • treatment with fremanezumab as chosen by treating physician

  • treatment with galcanezumab as chosen by treating physician

06

What researchers measure

Primary outcomes

  1. Change in Migraine days per month (= 4 weeks) from baseline to month 6

    Either of the following: (i) patient has treated headache with a triptan (ii) criteria C+ D for migraine without aura are fulfilled (iii) criteria B+C for migraine with aura are fulfilled

    Time frame: 6 months

Secondary outcomes

  1. Change in headache days per month (= 4 weeks) from baseline to month 6

    Any day with headache

    Time frame: 6 months

  2. Change in aura days per month (= 4 weeks) from baseline to month 6

    Any day with at least one migraine aura

    Time frame: 6 months

  3. Change in days with acute headache medication per month (= 4 weeks) from baseline to month 6

    Any days on which medication against migraine was taken by the patient

    Time frame: 6 months

  4. Change in days with triptans per month (= 4 weeks) from baseline to month 6

    Any days on which triptans medication were taken by the patient

    Time frame: 6 months

  5. Change in headache intensity from baseline to month 6

    Usual intensity of headche attacks on a numerical rating scale from 1 -10. Higher numbers indicate more severe headache attacks

    Time frame: 6 months

  6. Change in unpleasantness of aura from baseline to month 6

    Usual unpleasantness of aura on a numerical rating scale from 1 -10. Higher numbers indicate more unpleasantness.

    Time frame: 6 months

  7. Change in migraine duration from baseline to month 6

    Usual duration of migraine headache attack

    Time frame: 6 months

  8. Change in migraine aura duration from baseline to month 6

    Usual duration of migraine aura

    Time frame: 6 months

Other outcomes

  1. Subjective change in quality of life from baseline to month 6

    3 point scale: improved, unchanged, worse

    Time frame: 6 months

  2. Change in MIDAS (Migraine Diasability Assessment Questionnaire) scores from baseline to month 6

    Migraine Disability Assessment Questionnaire. A higher Score indicates more disability. mnimum = 0, maximum =270

    Time frame: 6 months

  3. Change in impact of headache from baseline to month 6

    Questionnaire. Higher scores indicate more impact of headache. Minmum= 36, maximum =38

    Time frame: 6 months

  4. Adverse events

    Any treatment emergent adverse events, Causality according to FDA rating: unlikely, possible, probable

    Time frame: Up to 36 months. Assessment every 3 months, may differ between study centers.

  5. Serious adverse events

    Definiation and causality according to FDA

    Time frame: Up to 36 months. Assessment every 3 months, may differ between study centers. Baseline refers to the 4 weeks interval before treatment start

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Sep 2025, 35 months after the start.

Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 35 months is above that.

Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Mar 16, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Sep 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Oct 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05281770
Lead sponsor
Austrian Migraine Registry Collaboration
Collaborators
Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Oct 1, 2022
Primary completion
Sep 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Oct 20, 2022

Study contacts

Franz Riederer, Prof
Contact
franz.riederer@uzh.ch
+436803279153
Karin Zebenholzer, Prof
Contact
karin.zebenholzer@meduniwien.ac.at
+43140400
Gregor Broessner, Prof
principal investigator · Medical University Innbruck

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion